Publish in this journal
Journal Information
Vol. 69. Issue 10.
Pages 997 (October 2016)
Vol. 69. Issue 10.
Pages 997 (October 2016)
Letter to the Editor
Full text access
Insufficient Lipid Control in Patients With Coronary Artery Disease: An Unresolved Problem. Response
Insuficiente control de parámetros lipídicos en pacientes con enfermedad coronaria: un problema por resolver. Respuesta
Enrique Galvea,
Corresponding author

Corresponding author:
, Alberto Corderob, Ángel Cequierc, José Ramón González-Juanateyd
a Servicio de Cardiología, Hospital General Universitario Vall d’Hebron, Barcelona, Spain
b Departamento de Cardiología, Hospital de San Juan, San Juan de Alicante, Alicante, Spain
c Servicio de Cardiología, Hospital Universitario de Bellvitge, L’Hospitalet de Llobregat, Barcelona, Spain
d Departamento de Cardiología, Complejo Hospitalario Universitario, Santiago de Compostela, A Coruña, Spain
Related content
Alfredo Renilla, Sergio Hevia, Vicente Barriales
Article information
Full Text
Download PDF
Full Text
To the Editor,

We thank Renilla et al. for their comments regarding our article on insufficient lipid control in patients with coronary artery disease,1 and we must agree with the majority of their comments and reflections.

The results of our study may appear somewhat disheartening, with good control (low-density lipoprotein [LDL] < 70 mg/dL) being achieved in only 26% of patients with coronary artery disease in Spain. However, we must bear in mind that this is an improvement: 95% of patients currently receive lipid-lowering therapy and 45% receive high-intensity lipid-lowering therapy; not too long ago, in 2006, 31% received no statins and only 10% received high-intensity therapy.2 It is true that there is a lack of awareness among professionals regarding the appropriate measures to avoid clinical inertia, but it is equally true that with a purely statin-based treatment, such ambitious targets are unlikely to be met. It is known that LDL-cholesterol is significantly reduced when treatment with statins is started (up to 50% if started directly on a high-intensity statin), but dose increases cause only small percentage decreases (7% to 9% when the dose is doubled); when ezetimibe is added, this can be up to 20%.3 Therefore, if high LDL values in patients on treatment are used as a means of evaluation, the target values will never be met. Renilla et al. also raised the point of the variable response to lipid-lowering therapy; regarding this, one of the most notable aspects of the REPAR study at one-year follow-up (data as yet unpublished) is that some of the patients that were initially well-controlled (LDL-cholesterol < 70 mg/dL) at the start of the study were no longer well-controlled at follow-up, despite unchanged lipid-lowering therapy.

Renilla et al. highlight the opportunity presented by the incorporation of PCSK9 inhibitors to the therapeutic arsenal. However, these drugs come with several limitations, as initial government guidelines4 indicate that these will be funded only for patients already on maximum treatment doses and with LDL-cholesterol levels > 100 mg/dL. This leaves a group of patients with LDL-cholesterol between 70mg/dL and 100mg/dL, which contains most of the patients who are already on treatment but are not well controlled, in a limbo with no therapeutic solution.

E. Galve, A. Cordero, A. Cequier, E. Ruiz, J.R. González-Juanatey.
Grado de control lipídico en pacientes coronarios y medidas adoptadas por los médicos. Estudio REPAR.
Rev Esp Cardiol., (2016),
[Epub ahead of print]. Available at:
A. Cordero, E. Galve, V. Bertomeu-Martínez, H. Bueno, L. Fácila, E. Alegría, et al.
Tendencias en factores de riesgo y tratamientos de pacientes con cardiopatía isquémica estable atendidos en consultas de cardiología entre 2006 y 2014.
Rev Esp Cardiol., 69 (2016), pp. 401-407
H.E. Bays, M. Averna, C. Majul, D. Muller-Wieland, A. De Pellegrin, H. Giezek, et al.
Efficacy and safety of ezetimibe added to atorvastatin versus atorvastatin uptitration or switching to rosuvastatin in patients with primary hypercholesterolemia.
Am J Cardiol., 112 (2013), pp. 1885-1895
Informe de posicionamiento terapéutico de evolocumab (Repatha®) en hipercolesterolemia. Madrid: Ministerio de Sanidad; 2016 [accessed 27 Jun 2016]. Available at:
Copyright © 2016. Sociedad Española de Cardiología
Revista Española de Cardiología (English Edition)

Subscribe to our newsletter

View newsletter history
Article options
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?